Advertisement

Topics

Genmab Announces Preliminary Cervical Cancer Data from Tisotumab Vedotin Phase I/II Study

19:06 EDT 16 Jun 2017 | Drugs.com

Copenhagen, Denmark; June 16, 2017 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today preliminary data from the ongoing Phase I/II study of tisotumab vedotin in solid tumors (GEN701). In Part 2 of the study, 11 of 34 evaluable patients in the...

Original Article: Genmab Announces Preliminary Cervical Cancer Data from Tisotumab Vedotin Phase I/II Study

NEXT ARTICLE

More From BioPortfolio on "Genmab Announces Preliminary Cervical Cancer Data from Tisotumab Vedotin Phase I/II Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...